Latest News and Press Releases
Want to stay updated on the latest news?
-
NEW YORK, April 03, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,...
-
NEW YORK, March 15, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage, immuno-oncology biopharmaceutical company focused on the acquisition,...
-
NEW YORK, March 13, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,...
-
Checkpoint Therapeutics Initiates Registrational Development Programs for Anti-PD-L1 Antibody CK-301
NEW YORK, Jan. 07, 2019 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,...
-
Checkpoint Therapeutics Reports Third Quarter 2018 Financial Results and Recent Corporate Highlights
NEW YORK, Nov. 02, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,...
-
NEW YORK, Oct. 16, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a clinical-stage immuno-oncology biopharmaceutical company focused on the acquisition,...
-
NEW YORK, Sept. 27, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a Fortress Biotech (NASDAQ: FBIO) company, today announced that James F. Oliviero, President...
-
Data were featured in an oral presentation at the IASLC 19th World Conference on Lung Cancer Phase 3 trial in treatment-naïve EGFR mutation-positive NSCLC patients targeted to commence in 2019 NEW...
-
6 of 8 pts (75%) ORR in treatment-naïve EGFR mutation-positive NSCLC patients Well-tolerated with unremarkable safety profile; No DLTs or related SAEs Phase 3 trial in treatment-naïve EGFR...
-
NEW YORK, Aug. 30, 2018 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (NASDAQ: CKPT), a Fortress Biotech (NASDAQ: FBIO) company, today announced that James F. Oliviero, President...